Erdosteine Therapy for Renal Failure: Current Perspectives

Erdosteine Therapy for Renal Failure: Current Perspectives

I read the recently published paper of Ebru Uz et al. (1), in the Nephro-Urology Monthly which focused on the renoprotective effects of erdosteine when it is used for cyclosporine-A (CsA) induced chronic nephrotoxicity. Erdosteine belongs to the class of mucolytics which is used for the treatment of wet cough and chronic obstructive pulmonary disease (CoPD). It has been reported that erdosteine...

erdosteine therapy for renal failure: current perspectives

Current issues and future perspectives of chronic renal failure.

Chronic renal disease is a major health issue in various parts of the world. The number of patients with end-stage renal disease (ESRD) is increasing in both developed and developing countries, greatly expanding the need for chronic dialysis and renal transplantation. In the year 2000, approximately 205,000 and 240,000 patients with ESRD were currently maintained on chronic dialysis in Japan an...

Enzyme Therapy: Current Perspectives.

Enzymes control all metabolic processes in human system from simple digestion of food to highly complex immune response. Physiological reactions occuring in healthy individuals are disturbed when enzymes are deficient or absent. Enzymes are administered for normalizing biological function in certain pathologies. Initially, crude proteolytic enzymes were used for the treatment of gastrointestina...

Renal denervation – current evidence and perspectives

Clinical trials have demonstrated that catheter-based renal denervation (RDN) reduces blood pressure and improves blood pressure control in patients with resistant hypertension. The follow-up data indicate that the blood pressure lowering effect of the procedure may last for up to 36 months. Despite the fact that RDN is a growing and promising technique, still more data from clinical trials are...